CA
BIO icon

Cetera Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cetera Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$404K Buy
+1,169
New +$384K ﹤0.01% 1746

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Cetera Advisors's BIO Position: Q1 2024 in Review

Cetera Advisors opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2024: 1,169 shares worth $404K. The stake represents ﹤0.01% of the portfolio and ranks #1746 among its holdings.

466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

  • Cetera Advisors held 1,169 shares of Bio-Rad Laboratories Class A worth $404K as of Q1 2024.
  • Bio-Rad Laboratories Class A was a new Cetera Advisors position in Q1 2024.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1746 holding.
  • 466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.